Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview

Moleculin Biotech

09/11/2026 21:36

Moleculin Biotech Inc MBRX.OQ MBRX.O is expected to  show no change in quarterly revenue when it reports  results on November 11 (estimated) for the period ending September 30 2026

​LSEG's mean analyst estimate for Moleculin Biotech Inc is for a loss of $8.87 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Moleculin Biotech Inc is $60.00, about 589.7% above its last closing price of $8.70
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-30.50
-31.07
-28.00
Beat
9.9
Mar. 31 2026
-33.30
-33.27
-70.80
Missed
-112.8
Dec. 31 2025
-1.28 hundred
-1.22 hundred
2.61 hundred
Beat
313.3​
Sep. 30 2025
-1.00 hundred
-97.50
-3.40 hundred
Missed
-248.7
​​Jun. 30 2025
-1.96 hundred
-1.82 hundred
-2.45 hundred
Missed
-34.9
Mar. 31 2025
-2.64 hundred
-2.77 hundred
-3.45 hundred
Missed
-24.3​
Dec. 31 2024
-6.65 hundred
-6.42 hundred
-1.86 hundred
Beat
70.9
Sep. 30 2024
-1.22 thousand
-1.22 thousand
-1.42 thousand
Missed
-16.8
This summary was machine generated November 9 at 21:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)